Evidence map›Paper›PMID 39315015›Full record

ArticleRSC advances2024

Benzenesulfonohydrazide-tethered non-fused and fused heterocycles as potential anti-mycobacterial agents targeting enoyl acyl carrier protein reductase (InhA) with antibiofilm activity.

Tarfah Al-Warhi, Ahmed Sabt, Małgorzata Korycka-Machala, Asmaa F Kassem, Moataz A Shaldam, Hoda Atef Abdelsattar Ibrahim, Malwina Kawka, Bożena Dziadek, Magdalena Kuzioła, Wagdy M Eldehna and 1 more

Abstract read
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Investigation of Potent Anti-Drug design, development and therapy · 2026
    Article
  2. Article
  3. Discovery ofFrontiers in chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tarfah Al-WarhiDepartment of Chemistry, College of Science, Princess Nourah bint Abdulrahman University Riyadh Saudi Arabia.
Ahmed SabtChemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre Dokki Cairo 12622 Egypt.ORCID https://orcid.org/0000-0001-6976-0196
Małgorzata Korycka-MachalaLaboratory of Genetics and Physiology of Mycobacterium, Institute of Medical Biology of the Polish Academy of Sciences Lodz Poland jdziadek@cbm.pan.pl.
Asmaa F KassemDepartment of Chemistry, College of Science and Humanities in Al-Kharj, Prince Sattam Bin Abdulaziz University Al-Kharj 11942 Saudi Arabia.
Moataz A ShaldamDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University Kafrelsheikh 33516 Egypt wagdy2000@gmail.com.ORCID https://orcid.org/0000-0002-0420-4364
Hoda Atef Abdelsattar IbrahimPediatric Department, Faculty of Medicine, Cairo University Cairo Egypt.ORCID https://orcid.org/0000-0001-5399-8861
Malwina KawkaDepartment of Molecular Microbiology, Faculty of Biology and Environmental Protection, University of Lodz Lodz Poland.
Bożena DziadekDepartment of Molecular Microbiology, Faculty of Biology and Environmental Protection, University of Lodz Lodz Poland.
Magdalena KuziołaLaboratory of Genetics and Physiology of Mycobacterium, Institute of Medical Biology of the Polish Academy of Sciences Lodz Poland jdziadek@cbm.pan.pl.
Wagdy M EldehnaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University Kafrelsheikh 33516 Egypt wagdy2000@gmail.com.ORCID https://orcid.org/0000-0001-6996-4017
Jarosław DziadekLaboratory of Genetics and Physiology of Mycobacterium, Institute of Medical Biology of the Polish Academy of Sciences Lodz Poland jdziadek@cbm.pan.pl.ORCID https://orcid.org/0000-0003-1427-884X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because resistant variants of the disease are always emerging, tuberculosis is a global issue that affects economies. New antitubercular medications should be developed, and this can be done by inhibiting druggable targets. Enoyl acyl carrier protein (ACP) reductase (InhA) is a crucial enzyme for the survival of

Identifiers

PMID39315015
PMCPMC11418391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.